Gentronix boosts analytical capabilities with automated slide scoring

Gentronix boosts analytical capabilities with automated slide scoring

Press release

28 September

Leading contract research organisation (CRO), Gentronix, has introduced a new service capability to its expanding toxicology offering, the 96-Well MNT with automated slide scoring.

This new assay will enable Gentronix to provide faster turnaround times, allowing rapid project decision-making with minimal compound requirements.

This service comprises a miniaturised version of a TK6 in vitro micronucleus test in which two treatment conditions are utilised in a 96-well microplate format across a range of test item concentrations, allowing for the evaluation and validation of the treatment conditions.

The Metafer classifier was validated by testing a range of nine known aneugens and clastogens as well as three non-genotoxic cytotoxic compounds. The reference set also included direct and indirect mutagens to demonstrate the suitability of the approach for genotoxins requiring metabolic activation.  All compounds in the reference set were correctly classified by the Metafer system and no significant or dose-related increases in micronuclei were observed for the non-genotoxic compounds.

Automated scoring results in faster delivery of data than manual slide scoring methods, allowing for faster delivery towards project timelines.

The addition to Gentronix’s portfolio comes shortly after the company announced a further laboratory and office expansion at its home at Alderley Park, Cheshire, in April, as part of the firm’s ongoing growth plan.

The previous expansions have accommodated the activities of the Big Blue® transgenic rodent mutation workflow and increased capacity for capacity for genetic, ocular, and skin toxicology testing - growing the Gentronix footprint at Alderley Park by 30%.

Matt Tate, CEO at Gentronix said:

“We are committed to providing the highest quality science for our expanding global client base. By adding the 96-Well MNT with automated slide scoring to our service capabilities, it will enable us to deliver even faster turnaround times for our clients and their projects.

“We are continuing our business growth journey this year and have already invested considerable effort into expanding our facilities and capacity and creating more high-quality jobs for the UK life science sector.”

By adding new services and increasing existing genetic toxicology service capacity to the market, Gentronix can turn around requests and testing quickly, with significant commercial advantages for clients, whilst facilitating the growth of the Gentronix business.

As a leading predictive toxicology CRO, Gentronix’ work helps develop safe products used by millions of people around the world including pharmaceuticals, agrochemicals, fragrances, foods, flavours, personal care products, and cosmetics.

For more information about Gentronix, please visit the website.